A large-scale trial of RTS,S – the world’s first malaria vaccine to provide partial protection – is due to commence in Malawi, Kenya and Ghana.
Browsing: Disease Area > Parasitic
A huge upsurge in malaria cases has been caused by Venezuela’s socioeconomic and political crisis, undoing years of progress and endangering neighbouring countries, according to research presented at ECCMID.
A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.
Take a look at this month’s industry headlines including Priority Review for two antibacterial agents from Merck (NJ, USA), a clinical trial for a new malaria drug and the launch of omadacycline in the USA.
A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
The accurate diagnosis of schistosomiasis, in both the mammalian and snail intermediate hosts as well as the environment, is extremely important in proper control and elimination. Despite multiple efforts over last few decades, the search for cheap, sensitive diagnostics for schistosomiasis is ongoing.
Some of the challenges with mass ivermectin administration could be addressed with new drugs or drug combinations with higher effect for the parasite – leading us to ask, what new treatments are currently in the clinical pipeline?
Want to discover the best research that’s occurred this year? Editor, Martha Powell, highlights the best of 2018’s infectious diseases research in an A–Z.
With progress plateauing for a second consecutive year and global financing also levelling off, the WHO has called for a ‘high burden to high impact’ country-led strategy.